MetLife Investment Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.98M Sell
11,490
-299
-3% -$55.4K 0.01% 1068
2025
Q4
$2.35M Sell
11,789
-410
-3% -$74.4K 0.01% 1001
2025
Q3
$1.91M Sell
12,199
-307
-2% -$48.8K 0.01% 1111
2025
Q2
$1.9M Sell
12,506
-771
-6% -$103K 0.01% 1021
2025
Q1
$2M Sell
13,277
-255
-2% -$42.8K 0.01% 1037
2024
Q4
$2.5M Buy
13,532
+117
+0.9% +$22.5K 0.01% 932
2024
Q3
$2.64M Sell
13,415
-315
-2% -$65.5K 0.02% 876
2024
Q2
$2.84M Buy
13,730
+1,730
+14% +$392K 0.02% 810
2024
Q1
$3.25M Sell
12,000
-441
-4% -$105K 0.02% 738
2023
Q4
$2.94M Sell
12,441
-229
-2% -$45K 0.02% 778
2023
Q3
$2.48M Sell
12,670
-311
-2% -$63.8K 0.02% 807
2023
Q2
$2.73M Sell
12,981
-2,016
-13% -$401K 0.02% 796
2023
Q1
$3.03M Sell
14,997
-153
-1% -$34.7K 0.02% 729
2022
Q4
$3.3M Sell
15,150
-293
-2% -$64K 0.03% 681
2022
Q3
$3.04M Sell
15,443
-160
-1% -$34.5K 0.03% 685
2022
Q2
$3.34M Sell
15,603
-203
-1% -$49.6K 0.03% 663
2022
Q1
$4.49M Buy
15,806
+4,656
+42% +$1.44M 0.03% 602
2021
Q4
$4.2M Sell
11,150
-233
-2% -$90.5K 0.03% 487
2021
Q3
$4.7M Sell
11,383
-268
-2% -$111K 0.04% 397
2021
Q2
$4.31M Sell
11,651
-14,056
-55% -$4.69M 0.04% 464
2021
Q1
$7.45M Sell
25,707
-1,513
-6% -$421K 0.07% 252
2020
Q4
$6.8M Sell
27,220
-1,224
-4% -$292K 0.06% 264
2020
Q3
$6.44M Sell
28,444
-944
-3% -$196K 0.07% 250
2020
Q2
$5.12M Buy
29,388
+1,354
+5% +$216K 0.06% 300
2020
Q1
$3.54M Hold
28,034
0.05% 368
2019
Q4
$4.28M Sell
28,034
-354
-1% -$49K 0.04% 428
2019
Q3
$3.76M Sell
28,388
-497
-2% -$66.6K 0.04% 476
2019
Q2
$4.1M Sell
28,885
-512
-2% -$69.4K 0.04% 447
2019
Q1
$4.27M Buy
29,397
+70
+0.2% +$9.2K 0.05% 410
2018
Q4
$3.32M Sell
29,327
-79
-0.3% -$9.89K 0.04% 488
2018
Q3
$3.96M Sell
29,406
-707
-2% -$87.3K 0.04% 491
2018
Q2
$3.38M Buy
30,113
+515
+2% +$55.7K 0.04% 535
2018
Q1
$3.16M Sell
29,598
-369
-1% -$39.8K 0.04% 575
2017
Q4
$3.28M Buy
+29,967
New +$3.26M 0.04% 593

Other funds holding CRL